Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unresectable Breast Carcinoma: early-phase trial registry
4 of 7 indexed Unresectable Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Unresectable Breast Carcinoma: 7 US clinical trials tracked, 4 recruiting.
Unresectable Breast Carcinoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Antonio Giordano, MD, running 1 of these trials.
Enrollment posture brief
Registry condition unresectable-breast-carcinoma
OPEN 4 | RECR 57% | LATE 0 | EARLY 6 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Unresectable Breast Carcinoma lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unresectable Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unresectable Breast Carcinoma is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Unresectable Breast Carcinoma trials is spread across many organizations.
Antonio Giordano, MD accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Unresectable Breast Carcinoma enrolment sits around 120 participants.
Median target enrolment is 120 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Unresectable Breast Carcinoma research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
BioNTech SE
NCT06827236
The COMPASSION Study
Dana-Farber Cancer Institute
NCT06507930
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
NCT03971409
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
NCT05372640
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Unresectable Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unresectable Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unresectable Breast Carcinoma page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Unresectable Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Antonio Giordano, MD sponsors the most Unresectable Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See Antonio Giordano, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Breast Carcinoma condition card totals 7 registered trials; most-linked intervention Recombinant Flt3 Ligand; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.